ClinicalTrials.gg
TerminatedNCT05307679Updated Aug 18, 2026Results posted

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

A Phase 2 interventional study of Basmisanil and Placebo in Dup15q Syndrome, sponsored by Hoffmann-La Roche. Terminated at 5 sites in 3 countries. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to sponsor decision and not related to safety or tolerability.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Study summary

This study consists of two parts. Part 1 will evaluate the safety, efficacy, and pharmacodynamics of 52-weeks of basmisanil treatment in children and adolescents (aged 2-14 years) with Dup15q syndrome. Part 1 will test the hypothesis that negative allosteric modulation of a GABAA receptor subtype can address excessive receptor function and positively impact core neurodevelopmental disease feature in individuals with Dup15q syndrome. Part 2 is an optional 2-year open-label extension to evaluate long-term safety, tolerability, and to provide supportive evidence of benefit of continued treatment with basmisanil in selected efficacy outcomes.

02

Conditions studied

  • Dup15q Syndrome

Keywords

  • dup15q
  • dup15q syndrome
  • 15q
  • duplication 15q
  • 15q duplication
  • chromosome 15q duplication
  • 15q duplication syndrome
  • duplication 15
  • triplication 15
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented maternal duplication (3 copies) or triplication (4 copies) of the chromosome 15q11.2-q13.1 region that includes the Prader Willi/Angelman critical region defined as [BP2-BP3] segment
  • Dup15q syndrome Clinician Global Impression of Severity scale (Dup15q CGI-S) overall severity score ≥ 4 (at least moderately ill)
  • Body weight equal to or above the third percentile for age
  • Participant has a parent, caregiver, or legally authorized representative (hereinafter "caregiver") of at least 18 years of age, who is fluent in the local language at the site, and capable and willing to provide written for the participant, according to International Council for Harmonisation and local regulations
  • Participant's caregiver must be living with the participant and, in the opinion of the Investigator, able and willing to reliably assess the participant's ongoing condition, to accompany the participant to all clinic visits, and ensure compliance to study treatment throughout the study. The same caregiver is able and willing to complete the caregiver assessments and is available to the Site by telephone or email if needed
  • Participant's caregiver is able and willing to use electronic devices to record information on the participant's condition and to complete assessments at home and agrees to home nursing visits, if local regulations allow for it and if home nursing service is available in the country/region

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled epilepsy at screening (as defined by the protocol)
  • Lymphoma, leukemia, or any within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • abnormalities at Screening
  • Clinically significant abnormalities in laboratory test results at screening (including positive results for , and/or )
  • Allowed prior existing medication should be on a stable regimen (or frequency of intervention) for at least 6 weeks, and at least 8 weeks for anti-epileptic treatment, prior to Screening
  • Non-pharmacological / behavioral therapies should not be stopped or newly started at least 6 weeks prior to Screening and are expected to remain stable for the entire study duration (excluding changes related to standard age and educational interventional programs and minor interruptions such as illness or vacation
  • Concomitant use of prohibited medications
  • Participation in an drug study within one month or within 6 × the elimination half-life, whichever is longer, prior to dosing in the study
  • Significant risk for suicidal behavior, as assessed through the suicidal behavior question adapted from the Columbia Classification Algorithm for Suicide Assessment (C-CASA) (participants ≥ 6 years of age only)
  • Known sensitivity to any of the study treatments or components thereof or drug or other allergy that, in the opinion of the Investigator, contraindicates the participation in the study, including severe lactose intolerance (e.g., unable to tolerate 250 mL [8 oz. or 1 cup] of milk, ice cream, or yogurt)
  • Concomitant clinically relevant disease or condition or any clinically significant finding at screening that could interfere with, or for which, the treatment might interfere with, the conduct of the study or that would pose an unacceptable risk to the participants in this study
  • Known active or uncontrolled bacterial, viral, or other infection (excluding fungal infections of nail beds) or any major clinically significant episode of infection or hospitalization (relating to the completion of the course of antibiotics) within 6 weeks prior to the start of drug administration
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Basmisanil

    Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of Part 1 of the trial (Day 365) or the end of Part 2 (Day 1095)

    Drug: Basmisanil

  • Placebo comparator
    Placebo

    Participants will receive oral placebo BID on the first day of treatment, then TID until the end of Part 1 of the trial (Day 365).

    Drug: Placebo

Interventions

  • Participants will receive oral basmisanil at age-appropriate dosages

  • DrugPlacebo

    Participants will receive oral placebo

06

What researchers measure

Primary outcomes

  1. Vineland-3 Adaptive Behavior Scales, 3rd Edition Composite Scores

    The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. Standard scores for the adaptive behavior composite range from 20-160; lower scores indicate lower adaptive functioning.

    Time frame: Baseline, Day 183, Day 365

Secondary outcomes

  1. Vineland-3 Gross and Fine Motor Subdomains Scores

    The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the gross and fine motor domains range from 1-24; lower scores indicate lower adaptive functioning.

    Time frame: Baseline, Day 183, Day 365

  2. Vineland 3 Expressive and Receptive Communication Subdomains

    The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the expressive and receptive communication subdomains range from 1-24; lower scores indicate lower adaptive functioning.

    Time frame: Baseline, Day 183, Day 365

  3. Vineland-3 Play and Leisure Time and Interpersonal Relationships Subdomains

    The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the play and leisure time, and interpersonal relationships subdomains range from 1-24; lower scores indicate lower adaptive functioning.

    Time frame: Baseline, Day 153, Day 365

  4. Mullen Scales of Early Learning (MSEL) Gross and Fine Motor Domains

    The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with total raw score ranges of 0-100 (gross motor) and 0-78 (fine motor). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

    Time frame: Baseline, Day 183, Day 365

  5. MSEL Visual Reception Domain Scores

    The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50. Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

    Time frame: Baseline, Day 183

  6. MSEL Expressive and Receptive Language Subdomains

    The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50 (expressive language) or 0-48 (receptive language). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

    Time frame: Baseline, Day 183

  7. Dup15q Syndrome Clinician Global Impression of Severity (CGI-S) Scale Scores

    The Dup15q CGI-S is a 10-domain clinician-rated measure on a 6-point scale that measures global severity of illness at a given point in time. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-none, 2-very mild, 3-mild, 4-moderate, 5-severe, and 6-very severe.

    Time frame: Baseline until Day 395, or early termination (prior to Day 395)

  8. Dup15q Syndrome Clinician Global Impression of Change Scale (CGI-C) Scores

    The Dup15q CGI-C is a 10-domain clinician-rated measure on a 7-point scale that assesses the clinician's impression of change in illness compared with baseline. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse. The CGI does not yield a global score.

    Time frame: Day 28 - Day 395 or early termination (prior to Day 395)

  9. Aberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C) Domain Scores - Irritability

    The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The irritability domain score range is 0-45, with higher score indicating greater severity.

    Time frame: Baseline - Day 365, or early termination (prior to Day 365)

  10. ABC-2-C Domain Scores - Social Withdrawal

    The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The social withdrawal domain score range is 0-48, with higher scores indicating greater severity.

    Time frame: Baseline - Day 365, or early termination (prior to Day 365)

  11. ABC-2-C Domain Scores - Stereotypic Behavior

    The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The stereotypic behavior subdomain score range is 0-21, with higher scores indicating greater severity.

    Time frame: Baseline - Day 365, or early termination (prior to Day 365)

  12. ABC-2-C Domain Scores - Hyperactivity/Non-Compliance

    The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The hyperactivity/non-compliance subdomain score range is 0-45, with higher scores indicating greater severity.

    Time frame: Baseline until Day 365, or early termination (prior to Day 365)

  13. ABC-2-C Domain Scores - Inappropriate Speech

    The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The inappropriate speech subdomain score range is 0-12, with higher scores indicating greater severity.

    Time frame: Baseline until Day 365, or early termination (prior to Day 365)

  14. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Up to 52 weeks

  15. Plasma Concentration of Basmisanil

    Time frame: Day 1 - Day 183

  16. Plasma Concentration of the Basmisanil Metabolite M1

    Time frame: Day 1 - Day 183

  17. Quantitative EEG (qEEG) Beta-band Power

    This is the average of the EEG parameter 10 x Log\_10 of the total beta power between 16 and 32 Hz in microVolt\^2.

    Time frame: Baseline, Day 14

07

Results

Posted Dec 12, 2025
Limitations and caveats
Data beyond certain timepoints (specified per outcome measure in the outcome measures section), or for timepoints for which n ≤ 1, is not reported due to concerns that certain demographic characteristics that may be present in only one treatment arm, or the duration a participant was in the trial, present an unacceptable risk of participant re-identification.

Participant flow

Participant flow — Overall Study
MilestonePlaceboBasmisanil
Started25
Completed00
Not completed25
Withdrew: Study terminated by sponsor or physician decision25

Outcome measures

PrimaryVineland-3 Adaptive Behavior Scales, 3rd Edition Composite Scores

The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. Standard scores for the adaptive behavior composite range from 20-160; lower scores indicate lower adaptive functioning.

Time frame:
Baseline, Day 183, Day 365
Reported as:
Median · Units on a scale
Vineland-3 Adaptive Behavior Scales, 3rd Edition Composite Scores
Units on a scalePlaceboBasmisanil
Baseline30.50 (30.0 to 31.0)36.00 (27.0 to 52.0)
Day 18328.00 (28.0 to 28.0)32.00 (32.00 to 32.00)
Day 36532.00 (32.00 to 32.00)—
SecondaryVineland-3 Gross and Fine Motor Subdomains Scores

The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the gross and fine motor domains range from 1-24; lower scores indicate lower adaptive functioning.

Time frame:
Baseline, Day 183, Day 365
Reported as:
Median · Units on a scale
Vineland-3 Gross and Fine Motor Subdomains Scores
Units on a scalePlaceboBasmisanil
Gross Motor V-Scale Score - Baseline1.00 (1.0 to 1.0)4.50 (1.0 to 8.0)
Gross Motor V-Scale Score - Day 1834.00 (4.00 to 4.00)—
Gross Motor V-Scale Score - Day 3651.00 (1.0 to 1.0)—
Fine Motor V-Scale Score - Baseline1.00 (1.0 to 1.0)3.00 (1.0 to 5.0)
Fine Motor V-Scale Score - Day 1831.00 (1.00 to 1.00)—
Fine Motor V-Scale Score - Day 3651.00 (1.00 to 1.00)—
SecondaryVineland 3 Expressive and Receptive Communication Subdomains

The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the expressive and receptive communication subdomains range from 1-24; lower scores indicate lower adaptive functioning.

Time frame:
Baseline, Day 183, Day 365
Reported as:
Median · Units on a scale
Vineland 3 Expressive and Receptive Communication Subdomains
Units on a scalePlaceboBasmisanil
Expressive Communication V-Scale Score - Baseline1.00 (1.0 to 1.0)1.00 (1.0 to 11.0)
Expressive Communication V-Scale Score - Day 1831.00 (1.0 to 1.0)1.00 (1.0 to 1.0)
Expressive Communication V-Scale Score - Day 3651.00 (1.0 to 1.0)—
Receptive Communication V-Scale Score - Baseline1.00 (1.0 to 1.0)1.00 (1.0 to 6.0)
Receptive Communication V-Scale Score - Day 1831.00 (1.0 to 1.0)1.00 (1.0 to 1.0)
Receptive Communication V-Scale Score - Day 3651.00 (1.0 to 1.0)—
SecondaryVineland-3 Play and Leisure Time and Interpersonal Relationships Subdomains

The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the play and leisure time, and interpersonal relationships subdomains range from 1-24; lower scores indicate lower adaptive functioning.

Time frame:
Baseline, Day 153, Day 365
Reported as:
Median · Units on a scale
Vineland-3 Play and Leisure Time and Interpersonal Relationships Subdomains
Units on a scalePlaceboBasmisanil
Play and Leisure V-Scale Score - Baseline1.00 (1.0 to 1.0)1.00 (1.0 to 9.0)
Play and Leisure V-Scale Score - Day 1831.00 (1.0 to 1.0)1.00 (1.0 to 1.0)
Play and Leisure V-Scale Score - Day 3651.00 (1.0 to 1.0)—
Interpersonal Relationships V-Scale Score - Baseline1.50 (1.0 to 2.0)1.00 (1.0 to 9.0)
Interpersonal Relationships V-Scale Score - Day 1833.00 (3.0 to 3.0)1.00 (1.0 to 1.0)
Interpersonal Relationships V-Scale Score - Day 3653.00 (3.0 to 3.0)—
SecondaryMullen Scales of Early Learning (MSEL) Gross and Fine Motor Domains

The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with total raw score ranges of 0-100 (gross motor) and 0-78 (fine motor). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

Time frame:
Baseline, Day 183, Day 365
Reported as:
Median · Units on a scale
Mullen Scales of Early Learning (MSEL) Gross and Fine Motor Domains
Units on a scalePlaceboBasmisanil
Gross Motor - Baseline20.50 (14.0 to 27.0)19.00 (13.0 to 35.0)
Gross Motor - Day 18324.00 (24.0 to 24.0)18.00 (18.0 to 18.0)
Gross Motor - Day 3651.00 (1.0 to 1.0)—
Fine Motor - Baseline15.50 (13.0 to 18.0)15.00 (6.0 to 30.0)
Fine Motor - Day 18318.00 (18.0 to 18.0)9.00 (9.0 to 9.0)
Fine Motor - Day 36511.00 (11.0 to 11.0)—
SecondaryMSEL Visual Reception Domain Scores

The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50. Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

Time frame:
Baseline, Day 183
Reported as:
Median · Units on a scale
MSEL Visual Reception Domain Scores
Units on a scalePlaceboBasmisanil
Baseline14.00 (11.0 to 17.0)4.00 (2.0 to 42.0)
Day 18321.00 (21.0 to 21.0)5.00 (5.0 to 5.0)
Day 36513.00 (13.0 to 13.0)—
SecondaryMSEL Expressive and Receptive Language Subdomains

The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50 (expressive language) or 0-48 (receptive language). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.

Time frame:
Baseline, Day 183
Reported as:
Median · Units on a scale
MSEL Expressive and Receptive Language Subdomains
Units on a scalePlaceboBasmisanil
Expressive Language - Baseline12.50 (12.0 to 13.0)17.00 (6.0 to 29.0)
Expressive Language - Day 18323.00 (23.0 to 23.0)6.00 (6.0 to 6.0)
Expressive Language - Day 3657.00 (7.0 to 7.0)—
Receptive Language - Baseline10.00 (7.0 to 13.0)16.00 (9.0 to 28.0)
Receptive Language - Day 18317.00 (17.0 to 17.0)11.00 (11.0 to 11.0)
Receptive Language - Day 36513.00 (13.0 to 13.0)—
SecondaryDup15q Syndrome Clinician Global Impression of Severity (CGI-S) Scale Scores

The Dup15q CGI-S is a 10-domain clinician-rated measure on a 6-point scale that measures global severity of illness at a given point in time. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-none, 2-very mild, 3-mild, 4-moderate, 5-severe, and 6-very severe.

Time frame:
Baseline until Day 395, or early termination (prior to Day 395)
Reported as:
Median · Units on a scale
Dup15q Syndrome Clinician Global Impression of Severity (CGI-S) Scale Scores
Units on a scalePlaceboBasmisanil
Baseline4.00 (4.0 to 4.0)4.00 (4.0 to 6.0)
Day 284.00 (4.0 to 4.0)4.00 (3.0 to 6.0)
Day 924.00 (4.0 to 4.0)4.00 (4.0 to 6.0)
Day 1834.00 (4.0 to 4.0)4.00 (4.0 to 4.0)
Day 2744.00 (4.0 to 4.0)—
Day 3654.00 (4.0 to 4.0)—
Follow-Up Day 395—5.00 (4.0 to 6.0)
Early Termination—6.00 (6.0 to 6.0)
SecondaryDup15q Syndrome Clinician Global Impression of Change Scale (CGI-C) Scores

The Dup15q CGI-C is a 10-domain clinician-rated measure on a 7-point scale that assesses the clinician's impression of change in illness compared with baseline. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse. The CGI does not yield a global score.

Time frame:
Day 28 - Day 395 or early termination (prior to Day 395)
Reported as:
Median · Units on a scale
Dup15q Syndrome Clinician Global Impression of Change Scale (CGI-C) Scores
Units on a scalePlaceboBasmisanil
Day 283.50 (3.0 to 4.0)3.00 (2.0 to 3.0)
Day 923.00 (3.0 to 3.0)3.00 (2.0 to 4.0)
Day 1834.00 (4.0 to 4.0)3.00 (3.0 to 3.0)
Day 2744.00 (4.0 to 4.0)—
Day 3653.00 (3.0 to 3.0)—
Follow-Up Day 395—3.00 (3.0 to 4.0)
Early Termination—4.00 (4.0 to 4.0)
SecondaryAberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C) Domain Scores - Irritability

The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The irritability domain score range is 0-45, with higher score indicating greater severity.

Time frame:
Baseline - Day 365, or early termination (prior to Day 365)
Reported as:
Median · Units on a scale
Aberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C) Domain Scores - Irritability
Units on a scalePlaceboBasmisanil
Baseline11.00 (11.0 to 11.0)15.00 (3.0 to 40.0)
Day 2810.00 (6.0 to 14.0)15.00 (5.0 to 18.0)
Day 9217.00 (17.0 to 17.0)16.00 (5.0 to 23.0)
Day 18320.00 (20.0 to 20.0)28.00 (28.0 to 28.0)
Day 27416.00 (16.0 to 16.0)—
Day 36513.00 (13.0 to 13.0)—
Early Termination—3.00 (3.0 to 3.0)
SecondaryABC-2-C Domain Scores - Social Withdrawal

The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The social withdrawal domain score range is 0-48, with higher scores indicating greater severity.

Time frame:
Baseline - Day 365, or early termination (prior to Day 365)
Reported as:
Median · Units on a scale
ABC-2-C Domain Scores - Social Withdrawal
Units on a scalePlaceboBasmisanil
Baseline14.50 (11.0 to 18.0)16.00 (2.0 to 25.0)
Day 287.50 (6.0 to 9.0)14.00 (7.0 to 17.0)
Day 9210.00 (10.0 to 10.0)12.00 (6.0 to 24.0)
Day 18310.00 (10.0 to 10.0)7.00 (7.0 to 7.0)
Day 2742.00 (2.0 to 2.0)—
Day 3654.00 (4.0 to 4.0)—
Early Termination—22.00 (22.0 to 22.0)
SecondaryABC-2-C Domain Scores - Stereotypic Behavior

The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The stereotypic behavior subdomain score range is 0-21, with higher scores indicating greater severity.

Time frame:
Baseline - Day 365, or early termination (prior to Day 365)
Reported as:
Median · Units on a scale
ABC-2-C Domain Scores - Stereotypic Behavior
Units on a scalePlaceboBasmisanil
Baseline8.00 (8.0 to 8.0)6.00 (0.0 to 15.0)
Day 285.50 (5.0 to 6.0)13.00 (7.0 to 16.0)
Day 926.00 (6.0 to 6.0)14.00 (8.0 to 15.0)
Day 1834.00 (4.0 to 4.0)6.00 (6.0 to 6.0)
Day 2748.00 (8.0 to 8.0)—
Day 3652.00 (2.0 to 2.0)—
Early Termination—11.00 (11.0 to 11.0)
SecondaryABC-2-C Domain Scores - Hyperactivity/Non-Compliance

The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The hyperactivity/non-compliance subdomain score range is 0-45, with higher scores indicating greater severity.

Time frame:
Baseline until Day 365, or early termination (prior to Day 365)
Reported as:
Median · Units on a scale
ABC-2-C Domain Scores - Hyperactivity/Non-Compliance
Units on a scalePlaceboBasmisanil
Baseline32.00 (23.0 to 41.0)19.00 (13.0 to 38.0)
Day 2812.00 (6.0 to 18.0)22.00 (15.0 to 33.0)
Day 9240.00 (40.0 to 40.0)18.00 (14.0 to 35.0)
Day 18339.00 (39.0 to 39.0)18.00 (18.0 to 18.0)
Day 27440.00 (40.0 to 40.0)—
Day 36533.00 (33.0 to 33.0)—
Early Termination—14.00 (14.0 to 14.0)
SecondaryABC-2-C Domain Scores - Inappropriate Speech

The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The inappropriate speech subdomain score range is 0-12, with higher scores indicating greater severity.

Time frame:
Baseline until Day 365, or early termination (prior to Day 365)
Reported as:
Median · Units on a scale
ABC-2-C Domain Scores - Inappropriate Speech
Units on a scalePlaceboBasmisanil
Baseline5.00 (2.0 to 8.0)2.00 (0.0 to 10.0)
Day 281.50 (0.0 to 3.0)0.00 (0.0 to 2.0)
Day 923.00 (3.0 to 3.0)0.00 (0.0 to 8.0)
Day 1831.00 (1.0 to 1.0)0.00 (0.0 to 0.0)
Day 2743.00 (3.0 to 3.0)—
Day 3652.00 (2.0 to 2.0)—
Early Termination—0.00 (0.0 to 0.0)
SecondaryIncidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Up to 52 weeks
Reported as:
Number · Count of Participants
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Count of ParticipantsPlaceboBasmisanil
AEs25
SAEs01
SecondaryPlasma Concentration of Basmisanil
Time frame:
Day 1 - Day 183
Reported as:
Mean · ng/mL
Plasma Concentration of Basmisanil
ng/mLBasmisanil
Day 1 - Hour 1.52520 ± 965
Day 1 - Hour 3.52220 ± 955
Day 1 - Hour 5.51640 ± 756
Day 1 - Hour 7.51040 ± 392
Day 1 - Hour 9791 ± 368
Day 2 - Hour 0731 ± 535
Day 2 - Hour 1.52380 ± 576
Day 2 - Hour 3.52210 ± 864
Day 14 - Hour -1.51210 ± 1230
Day 14 - Hour 0902 ± 973
Day 14 - Hour 1.52480 ± 355
Day 14 - Hour 3.52160 ± 698
Day 92 - Hour 0896 ± 689
SecondaryPlasma Concentration of the Basmisanil Metabolite M1
Time frame:
Day 1 - Day 183
Reported as:
Mean · ng/mL
Plasma Concentration of the Basmisanil Metabolite M1
ng/mLBasmisanil
Day 1 - Hour 1.51410 ± 585
Day 1 - Hour 3.51510 ± 417
Day 1 - Hour 5.5985 ± 335
Day 1 - Hour 7.5675 ± 221
Day 1 - Hour 9535 ± 173
Day 2 - Hour 0664 ± 568
Day 2 - Hour 1.51330 ± 358
Day 2 - Hour 3.51410 ± 506
Day 14 - Hour -1.51400 ± 1410
Day 14 - Hour 01060 ± 1470
Day 14 - 1.51510 ± 413
Day 14 - Hour 3.51250 ± 540
Day 92 - Hour 0648 ± 522
SecondaryQuantitative EEG (qEEG) Beta-band Power

This is the average of the EEG parameter 10 x Log\_10 of the total beta power between 16 and 32 Hz in microVolt\^2.

Time frame:
Baseline, Day 14
Reported as:
Mean · µV2
Quantitative EEG (qEEG) Beta-band Power
µV2PlaceboBasmisanil
Baseline9.47 ± 0.2111.39 ± 1.55
Day 149.44 ± 0.379.74 ± 1.05

Adverse events

Collected over Baseline - Day 365. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Basmisanil0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboBasmisanil
Unspecified SAEGeneral disorders0/21/5
Most frequent other events
Most frequent other events
EventPlaceboBasmisanil
Incorrect dose administeredInjury, poisoning and procedural complications2/23/5
Unspecified AEGeneral disorders1/22/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBasmisanilTotal
Mean8.0 ± 1.48.8 ± 2.28.6 ± 1.9
Sex/Gender, Customized
Sex/Gender, Customized(Count of Participants)PlaceboBasmisanilTotal
Female + Male257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBasmisanilTotal
Hispanic or Latino——0
Not Hispanic or Latino——0
Unknown or Not Reported——0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBasmisanilTotal
American Indian or Alaska Native——0
Asian——0
Native Hawaiian or Other Pacific Islander——0
Black or African American——0
White——0
More than one race——0
Unknown or Not Reported——0
08

Study locations

5 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90010, United States
  • Rush University Medical Center
    Chicago, Illinois 60612-3244, United States
  • Hospital Sant Joan De Deu
    Esplugues de Llobregas, Barcelona 08950, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Evelina London Children's Hospital
    London, SE1 7EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Mar 2024, 14 months.

Results were first posted in Dec 2025, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 1, 2022
StartActual
Dec 16, 2022
Primary completionActual
Mar 4, 2024
CompletionActual
Mar 4, 2024
Results first posted
Dec 12, 2025
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05307679
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Dec 16, 2022
Primary completion
Mar 4, 2024
Completion
Mar 4, 2024
Results posted
Dec 12, 2025
Last update
Aug 18, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion